Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting

被引：0

作者：

Shah, Rajiv

Reck, Martin

Grohe, Christian

Christoph, Daniel Christian

Buchmeier, Eva Lotte

Saalfeld, Felix Carl

Frost, Nikolaj

Kopp, Hans-Georg

Faehling, Martin

Griesinger, Frank

Roeper, Julia

Hoffknecht, Petra

Kuon, Jonas

Luan, Jingting

Chesi, Paolo

Christopoulos, Petros

Thomas, Michael

机构：

[1] Heidelberg Univ Hosp, Dept Thorac Oncol, Heidelberg, Germany

[2] NCT Heidelberg, Natl Ctr Tumor Dis, Heidelberg, Germany

[3] TLRC H, Heidelberg, Germany

[4] German Ctr Lung Res, Heidelberg, Germany

[5] German Ctr Lung Res DZL, Lungen Clin Grosshansdorf, Airway Res Ctr North ARCN, Grosshansdorf, Germany

[6] Evangel Lungenklin Berlin, Klin Pneumol, Berlin, Germany

[7] Evang Kliniken Essen Mitte, Dept Med Oncol, Essen, Germany

[8] Klinikum Stadt Koln gGmbH, Cologne, Germany

[9] Univ Hosp Dresden, Clin Internal Med 1, Dresden, Germany

[10] Charite Univ Med Berlin, Berlin, Germany

[11] Free Univ Berlin, Berlin, Germany

[12] Humboldt Univ, Berlin, Germany

[13] Berlin Inst Hlth, Berlin, Germany

[14] Klin Schillerhohe, Robert Bosch Ctr Tumorerkrankungen, Stuttgart, Germany

[15] Klinikum Esslingen GmbH, Dept Pneumol, Esslingen, Germany

[16] Univ Med Oldenburg, Univ Dept Internal Med Oncol, Pius Hosp, Dept Hematol & Oncol, Oldenburg, Germany

[17] Univ Klin Innere Med Onkol, PIUS Hosp Oldenburg, Oldenburg, Germany

[18] Franziskus Hosp Harderberg, Dept Oncol, Niels Stensen Kliniken, Georgsmarienhutte, Germany

[19] SLK Fachklin Lowenstein, Lowenstein, Germany

[20] Sapienza Univ Rome, Dept Med Oncol, Policlin Umberto 1, Rome, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8085

引用

页数：1

共 50 条

[1] Real-world Study on Efficacy of First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso)
Aguirre, E. D.
Enrico, D. H.
Tissera, N. S.
Tsou, F.
Pupareli, C.
Peralta, D.
Waisberg, F.
Rodriguez, A.
Kaen, D.
Recondo, G.
Ramos, M.
Bluthgen, V.
Castagneris, N.
Perfetti, A.
Levit, P.
Chacon, M.
Corrales, L.
Arrieta, O.
Cardona, A. F.
Martin, C.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S382 - S382
[2] Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM)
Enrico, Diego
Gomez, Juan Elias
Aguirre, Danilo
Tissera, Natalia Soledad
Tsou, Florencia
Pupareli, Carmen
Tanco, Delfina Peralta
Waisberg, Federico
Rodriguez, Andres
Rizzo, Manglio
Minatta, Nicolas
Rafael, Picon
Basbus, Luis
Lupinacci, Lorena
Kaen, Diego
Ramos, Mauro
Bluthgen, Virginia
Castagneris, Nicolas
Coppola, Maria Pia
Scocimarro, Alejandra
Guerra, Maria Florencia
Perfetti, Aldo
Levit, Patricio
Galvez-Nino, Marco
Mas, Luis
Rojas, Leonardo
Zuluaga, Jairo
Chacon, Matias
Corrales, Luis
Samtani, Suraj
Arrieta, Oscar
Cardona, Andres
Remon, Jordi
Martin, Claudio
CLINICAL LUNG CANCER, 2024, 25 (08)
[3] The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab plus nivolumab vs. nivolumab in a real-world setting
Billard, Karine
Mortier, Laurent
Dereure, Olivier
Dalac, Sophie
Montaudie, Henri
Legoupil, Delphine
Dutriaux, Caroline
De Quatrebarbes, Julie
Maubec, Eve
Leccia, Marie-Therese
Granel-Brocard, Florence
Brunet-Possenti, Florence
Arnault, Jean-Philippe
Gaudy-Marqueste, Caroline
Pages, Cecile
Saiag, Philippe
L'Orphelin, Jean-Matthieu
Zehou, Ouidad
Lesimple, Thierry
Allayous, Clara
Porcher, Raphael
Oriano, Bastien
Dalle, Stephane
Lebbe, Celeste
BRITISH JOURNAL OF DERMATOLOGY, 2025,
[4] Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma
Dumoulin, D. W.
Douma, L. H.
Hofman, M. M.
van der Noort, V.
Cornelissen, R.
de Gooijer, C. J.
Burgers, J. A.
Aerts, J. G. J. V.
LUNG CANCER, 2024, 187
[5] Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Schmid, S.
Holer, L.
Frueh, M.
Koster, K-L.
Rothschild, S. I.
Britschgi, C.
Boos, L.
Frehner, L.
Almeida, S. Cardoso
Metaxas, Y.
Mark, M. T.
Froesch, P. R.
Janthur, W-D.
Allemann, A. T.
Waibel, C.
Vonder Muhll-Schill, C.
Cerciello, F. W. F.
Mauti, L. A.
ANNALS OF ONCOLOGY, 2023, 34 : S1133 - S1134
[6] Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
Schmid, Sabine
Holer, Lisa
Gysel, Katrin
Koster, Kira-Lee
Rothschild, Sacha I.
Boos, Laura A.
Frehner, Lorenz
Almeida, Sabine Cardoso
Britschgi, Christian
Metaxas, Yannis
Mark, Michael
Froesch, Patrizia
Janthur, Wolf-Dieter
Allemann, Anna
Waibel, Christine
von der Muhll-schill, Catherine
Fruh, Martin
Mauti, Laetitia A.
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (12):
[7] New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
Laune, Quentin
Brosseau, Solenn
BULLETIN DU CANCER, 2022, 109 (01) : 4 - 6
[8] Follow-Up after First-Line Nivolumab Plus Ipilimumab in Patients with Pleural Mesothelioma: A Real-World Dutch Cohort Study (FLORA-Study)
Douma, L. H.
Hofman, M. M.
Zwierenga, F.
Buma, A. I. G.
Schouwink, J. H.
Burgers, J. A.
Smesseim, I.
Dumoulin, D. W.
Aerts, J. G. J. V.
de Gooijer, C. J.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S71 - S71
[9] Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab
Kozak, Katarzyna
Teterycz, Pawel
Galus, Lukasz
Mackiewicz, Jacek
Galwas-Kliber, Katarzyna
Kaminska-Winciorek, Grazyna
Brandys, Piotr
Cybulska-Stopa, Bozena
Kempa-Kaminska, Natasza
Zietek, Marcin
Zubrowska, Justyna
Dziura, Robert
Dembinski, Mateusz
Bereza, Michal
Czarnecka, Anna Malgorzata
Rutkowski, Piotr
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Real-World Evidence of Ipilimumab Plus Nivolumab Combination Therapy in Patients with Malignant Pleural Mesothelioma
Kondo, T.
Otsuki, T.
Kato, M.
Murata, T.
Mori, M.
Ota, H.
Wakita, H.
Kandori, T.
Kiyota, J.
Higashiyama, T.
Tokuda, M.
Tada, A.
Negi, Y.
Horio, D.
Fujimoto, D.
Mikami, K.
Takahashi, R.
Minami, T.
Kuribayashi, K.
Kijima, T.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S276 - S277

← 1 2 3 4 5 →